The Role of COX-2 Selective Inhibitors in the Treatment of Patients with Breast Cancer

The possibility of COX-2 selective inhibitor use in the treatment of patients with malignancies has been considered. A group of COX-2 selective inhibitors has been presented with coxibs: celecoxib, NS-398, nimesulide, meloxicam. There has been demonstrated the role of the COX-2 blockers in risk decrease of four most common malignant tumors: breast cancer (by 71%), prostate cancer (by 55%), colon cancer (by 70%) and lung cancer (by 79%). The role of COX-2 inhibitors in the prevention of developing resistance to chemotherapy in the breast cancer cells has been studied. There has been presented the data of the COX-2 inhibitors use as an antitumor treatment component in patients with a metastatic breast cancer in combinations with hormonal treatment in a hormone-positive breast cancer, as well as the results of neoadjuvant combined therapy in patients with a locally advanced cancer in a menopause. The findings presented are indicative of the expediency of the COX-positive tumor selection into a separate group for management optimization and the use of the possibilities of the enzyme expression target control.

Kolyadina I.V., Poddubnaya I.V., Komov D.V., Rostchin E.M., Ozhereliev A.S., Orinovsky M.B. The Role of COX-2 Selective Inhibitors in the Treatment of Patients with Breast Cancer. Sovremennye tehnologii v medicine 2011; (1): 108